STUDY: Tincture of Cannabis to treat “Cannabis Dependency”?

Last month, the Journal of American Medicine (JAMA) Internal Medicine released a study claiming Nabiximols successfully “reduced illicit cannabis use in patients with cannabis dependence.” The study was poorly designed and meaningless, and the subsequent article was short on logic and facts. Let’s review them. Nabiximols, or GW Pharmaceuticals’ Sativex, is a standardized cannabis tincture with an equal dose of CBD and THC. It is essentially a whole plant cannabis extract. Nabiximols is replacing “illicit”, or illegal,  cannabis use only by the default of it being in the early stages of FDA...
More

Older Adults Tolerate Medical Marijuana Well

From: Grandmas Smoking Weed The following article is an excellent example of the value of community-based and patient-centered observational study in developing a better understanding of the therapeutic usefulness of cannabinoid-based medicine for specific conditions, in this case chronic pain and opioid analgesic dependence. The fact that it was carried out through chart review in a clinic seeing mostly older adults is all the more encouraging, as the efficacy and tolerability of THC-containing cannabis medicines among the elderly might be expected to be lower than among younger populatio...
More

NORML: Cannabis Exposure Not Associated With Significant Changes In Brain Morphology

For Immediate Release Contact: Paul ArmentanoNORML Deputy Director Paul@norml.org Cannabis exposure is not associated with significant changes in brain morphology in either older or younger subjects, according to a pair of newly published studies. Commenting on the two studies, NORML Deputy Director Paul Armentano said: “These findings dispute the long-standing ‘stoner-stupid’ stereotype and should help to assuage fears that cannabis’ acute effects on neurocognitive behavior may persist long after drug ingestion, or that cannabis exposure is associated with any sort of signifi...
More

Study: Review of CBD for treatment-resistant epilepsy

This recent clinical trial concerning cannabidiol (CBD) and seizure disorders demonstrated that “CBD might reduce seizure frequency and an adequate safety profile in children and young adults with highly treatment-resistant epilepsy.” In 2016, doctors across the United States began an open-label interventional trial focused on patients (aged 1–30 years) with severe, intractable, childhood-onset, treatment-resistant epilepsy. These patients were all receiving stable doses of anti-epileptic medications prior to study entry and were enrolled in an expanded-access program at 11 epilepsy cente...
More